TCRVβ2-Targeted ADCs Show Promise for Precision T Cell Cancer Therapy
A recent study published in Blood Advances demonstrates how site-specific antibody-drug conjugates (ADCs) targeting TCRVβ2 can selectively eliminate malignant T cells while sparing most healthy T cells. Using our GlyCLICK® technology, the researchers generated homogeneous anti-TCRVβ2 ADCs with defined drug-to-antibody ratios and potent anti-tumor activity both in vitro and in vivo. Patients with advanced cutaneous…













